NIH Funds Influenza Research and Surveillance Network
Influenza scientists at five sites in the US are to receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to collaborate with investigators around the globe in a network designed to advance understanding of influenza viruses and how they cause disease.
In addition to basic research, investigators in the Centers of Excellence for Influenza Research and Surveillance (CEIRS) network also conduct domestic and international influenza surveillance studies with an emphasis on rapid characterization of viruses that have the potential to cause pandemics. The first CEIRS network was launched in 2007 by NIAID, part of the National Institutes of Health. NIAID today announced awards of the new contracts to continue the programme for 7 years.
“The CEIRS network exemplifies NIAID’s dual mission of conducting basic and applied influenza research, while maintaining the ability to respond rapidly in the event of an emerging public health threat,” said NIAID Director Anthony S. Fauci, MD. “CEIRS investigators have contributed greatly to our understanding of how influenza viruses emerge from wild and domestic animals, their adaptation to and global circulation throughout the human population and the interplay between the viruses and human immune responses.” Dr Fauci added that the CEIRS network also played a critical role in the nation’s response to the 2009 H1N1 influenza pandemic by, for example, quickly characterizing the virus and performing pre-clinical testing of candidate vaccines.
The geographic range of sample collection sites will be more tightly focused than previously on those regions where new influenza viruses are likely to emerge and the network will further integrate basic research with surveillance data gathering, said CEIRS project officer Diane Post, PhD, of NIAID’s Division of Microbiology and Infectious Diseases.
“A key mission of the CEIRS network is to foster innovative and collaborative basic research on influenza viruses, including how they evolve and adapt to animal and human hosts. The information we gain could help us understand why influenza pandemics occur and could assist health officials in taking steps to mitigate outbreaks,” Dr Post said.
Four of the new CEIRS contracts are to institutions that had received a 2007 award. One institution, Johns Hopkins University, will establish a new center. All will conduct surveillance and basic research projects. The network has a global reach, with collaborations established or planned at more than two dozen sites in Asia, Southeast Asia, the Middle East, South America, Europe and Australia. Funding for the first year of the contracts will total approximately $23 million.
“Proposed work from all five centers involves new and exciting research programs that hold the promise to answer fundamental questions pertaining to influenza in animals and people,” said Dr Post.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance